You could be eligible for a new phase II trial for CIDP

(chronic inflammatory demyelinating polyradiculoneuropathy)

RECRUITING NOW: RDMD is recruiting patients for CIDP research, including a new phase II clinical trial. You can read more about the trial at

To move this research forward, we need to pre-screen 200 patients. Patients cleared by RDMD are more likely to qualify for the trial. If you are not a good match, or aren’t interested in this trial, you can still participate in future RDMD CIDP research by joining below.

0/200 joined
Complete the sign up in 10-15 minutes and we do the work to complete your pre-screen.
Mens Health Magazine
Mens Health Magazine
Village Global
Village Global

Who’s involved?

Reza Seyedsadjadi - (Consultant - Assistant in Neurology MGH)
Reza Seyedsadjadi - (Consultant - Assistant in Neurology MGH)
RDMD Research for CIDP is approved and monitored by an independent ethics review board called WIRB (Western Institutional Review Board). WIRB is a group of people who review research studies to protect the rights and welfare of human subjects. They provide in-depth regulatory expertise to support development of research protocols and documentation.Read more.

Why join the CIDP program?

Key benefits for you:

Reduce the time for chronic inflammatory demyelinating polyradiculoneuropathy drug development

All your medical data in one place

Follow new clinical trials

Make your de-identified health information part of multiple research projects

Your dashboard
Your dashboard

For the future

For the future

Help researchers get the information they need to advance development of new drug and gene therapies.

For the CIDP community

For the CIDP community

Jumpstart research and increase knowledge and understanding of chronic inflammatory demyelinating polyradiculoneuropathy.

For you

For you

See all your records in one place. Track how you are contributing to research and be notified about new clinical trials.

How it works

Sign up

1. Sign up

Create your private account and review our research consent (takes about 10 minutes)

We get to work

2. We get to work

We do all the behind-the-scenes work to retrieve and process your records

Empower research

3. Empower research

Track your contribution to research projects and, based on your records, find out if you qualify for new clinical trials based on your records

Be part of research

Questions? Check out our FAQ

Clinical trials for CIDP

Stay in the loop. We’re monitoring chronic inflammatory demyelinating polyradiculoneuropathy clinical trials that may be interesting for patients. We can contact you if we find potentially matching trials, and keep you up to date if there are new trials or changes.

Join the CIDP program

Tracking 5 trials

UCB Biopharma S.P.R.L.Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Nagoya UniversityRecruiting

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

OctapharmaActive, not recruiting

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

Baxalta now part of ShireRecruiting

Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP

Fondation Ophtalmologique Adolphe de RothschildRecruiting

Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

See for more information

Our values & principles.

Patients own their data

We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.

We protect patient privacy

We abide by a strict research consent and privacy policy. We only share de-identified data with researchers, foundations, and therapeutic companies with patients’ consent. Protecting the privacy of patients and ensuring the security of their information is our highest priority.

Researchers gain access

We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.

Inclusiveness in the community

We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.

Driving forward therapeutic development

Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.

How we got started

“Patients shouldn’t be bystanders in drug development.”

– Onno Faber (Founder of RDMD)

Four years ago, I started experiencing hearing loss in my left ear. Doctors prescribed me steroids, thinking it was an infection, but the deterioration did not slow down. After numerous failed treatments, a specialist finally ordered an MRI, whereupon he discovered a large tumor on my left hearing nerve. Months later, another tumor was discovered in my right hearing nerve, and another on my spine. I was diagnosed with a rare genetic disease called NF2 (Neurofibromatosis Type 2), a disease that affects only 1 in 30,000 people. It completely changed my perspective.

All my life, I’ve been a technology entrepreneur, beginning with a tech company I started in high school. I’m now applying everything I’ve learned throughout my career to build RDMD, where we’re helping to accelerate treatments for patients with rare disease. Our mission is ambitious, but I can’t imagine working on anything more important than this.

– Onno

Onno FaberPhoto Credit: from by Damien Maloney

Our work with CIDP research

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-related neurological condition that causes damage to peripheral nerves. The cause of CIDP is not fully understood. Most patients are diagnosed between the ages of 40 and 60. In CIDP, nerve damage causes progressive leg and arm weakness that makes it difficult to walk, go up stairs, and perform fine motor skills. Many patients also have reduced sensory function, which can cause loss of sensation, tingling, numbness, and issues with balance. Current treatment for CIDP includes steroids, plasma exchange, intravenous immunoglobulin, and other immunomodulatory drugs. While these treatments are effective in some patients, they do not work for everyone, and many patients experience relapses. New treatments are needed to make sure more CIDP patients can experience a reduction of their symptoms.

RDMD drives research on your condition as well as research on general health and wellness.

  • Jumpstart
  • Accelerate
  • Insights

The CIDP program is in the jumpstart stage.

Be part of research